All News

21 February 2008

MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody TherapiesAntibodies

21 February 2008

Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanomaAntibodies

20 February 2008

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone LossAntibodies

19 February 2008

InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast CancerAntibodies

19 February 2008

Biolex Therapeutics Enters Into Agreement With Merck KGaA for Antibody OptimizationAntibodies

18 February 2008

Takeda Discontinues Development of MatuzumabAntibodies

18 February 2008

EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus RoyaltiesAntibodies

13 February 2008

Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpointAntibodies

13 February 2008

Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of AdenocarcinomasAntibodies

13 February 2008

YM BioSciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain CaincerAntibodies

12 February 2008

Sanofi-aventis enters into Antibody Agreements with Dyaxand “Phage Display Technology”Antibodies

12 February 2008

Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.Antibodies

12 February 2008

MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 ProgramAntibodies

11 February 2008

2008 is a decisive year for the validation of the asthma target interleukin-13Antibodies

11 February 2008

FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCANAntibodies

8 February 2008

Clinical Experience With Peregrine’s Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic AgentsAntibodies

8 February 2008

Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemiaAntibodies

7 February 2008

InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin’s Lymphoma With Leading Marketed ProductAntibodies

7 February 2008

Human Genome Sciences and Xencor Announce Genoma CollaborationAntibodies

6 February 2008

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal AntibodyAntibodies

6 February 2008

OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis CAntibodies

6 February 2008

FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid ArthritisAntibodies

5 February 2008

FDA Gives Green Light to Lpath’s ASONEP(TM) IND SubmittalAntibodies

4 February 2008

MedImmune Submits Biologics License Application to FDA for MotavizumabAntibodies

4 February 2008

Promising Phase 3 Data for Ustekinumab (Cnto 1275) in Long-Term Improvement of Chronic Plaque PsoriasisAntibodies

4 February 2008

Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDAAntibodies

2 February 2008

Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque PsoriasisAntibodies

1 February 2008

ImmunoGen, Inc. Earns Milestone with IND Filing for BIIB015Antibodies

1 February 2008

New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque PsoriasisAntibodies

31 January 2008

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease PatientsAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Aflibercept (Eylea) Biosimilars Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

TSLP Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review